Rimantadine


Generic Medicine Info
Indications and Dosage
Oral
Prophylaxis of influenza A
Adult: 100 mg bid.
Child: 1-9 years 5mg/kg daily in 1 or 2 divided doses. Max: 150 mg daily. ≥10 years Same as adult dose.
Elderly: 100 mg daily.

Oral
Influenza A
Adult: 100 mg bid for 7 days.
Elderly: 100 mg daily.
Renal Impairment
CrCl (mL/min) Dosage
<30 100 mg daily.
Hepatic Impairment
Severe: 100 mg daily.
Contraindications
Hypersensitivity.
Special Precautions
Patient with a history of seizure disorder. Elderly. Hepatic and renal impairment. Pregnancy and lactation.
Adverse Reactions
Significant: Seizure.
Gastrointestinal disorders: Nausea, vomiting, abdominal pain, xerostomia.
General disorders and administration site conditions: Fatigue.
Metabolism and nutrition disorders: Anorexia.
Nervous system disorders: Headache, dizziness.
Psychiatric disorders: Insomnia, nervousness.
Monitoring Parameters
Assess the elderly, or patients with hepatic or renal impairment for CNS or gastrointestinal adverse effects.
Drug Interactions
Decreased plasma concentrations with paracetamol and aspirin. May diminish the therapeutic effect of influenza virus vaccines.
Action
Description: Rimantadine, an adamantane derivative, synthetic antiviral agent that exerts its effect on influenza A virus (H1N1, H2N2, H3N2) early in the viral replicative cycle which possibly inhibits the uncoating of the virus.
Pharmacokinetics:
Absorption: Well absorbed from the gastrointestinal tract. Time to peak plasma concentration: 6 hours.
Distribution: Volume of distribution: 727-728 L. Plasma protein binding: Approx 40%, mainly to albumin.
Metabolism: Metabolised in the liver via hydroxylation and glucuronidation.
Excretion: Via urine (<25% as unchanged drug). Elimination half-life: 25.4 hours (range: 13-65 hours).
Chemical Structure

Chemical Structure Image
Rimantadine

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5071, Rimantadine. https://pubchem.ncbi.nlm.nih.gov/compound/Rimantadine. Accessed Nov. 25, 2020.

Storage
Store at 25°C.
MIMS Class
ATC Classification
J05AC02 - rimantadine ; Belongs to the class of thiosemicarbazone antivirals. Used in the systemic treatment of viral infections.
References
Anon. Rimantadine. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 22/10/2020.

Anon. Rimantadine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 22/10/2020.

Buckingham R (ed). Rimantadine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 22/10/2020.

Rimantadine Hydrochloride Tablet, Film Coated (Amneal Pharmaceuticals of New York LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 22/10/2020.

Disclaimer: This information is independently developed by MIMS based on Rimantadine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in